Endothelin ETA receptor-subtype specific antagonism does not mitigate the acute systemic or renal effects of exogenous angiotensin II in humans

Eur J Clin Invest. 2002 Apr;32(4):230-5. doi: 10.1046/j.1365-2362.2002.00974.x.

Abstract

Background: Angiotensin II (Ang II) is assumed to play a pathophysiological role in a variety of vascular diseases. Animal studies indicate that these effects are partly attributed to stimulation of endothelin-1 (ET-1) release. The aim of the present study was to investigate whether the acute effects of Ang II on systemic and renal haemodynamics in healthy subjects can be influenced by endothelin ET(A)-receptor blockade.

Design: The study design was balanced, randomized, placebo-controlled, double blind, two-way cross-over, in 10 healthy male subjects.

Methods: Subjects received stepwise increasing intravenous doses of Ang II (0.65, 1.25, 2.5, 5 ng kg(-1) min(-1) for 15 min per dose level) in the presence or absence of BQ-123 (60 microg min(-1)), a specific ETA-receptor antagonist. Renal plasma flow (RPF) and glomerular filtration rate (GFR) were assessed by the para-aminohippurate and inulin plasma clearance method, respectively. Renal vascular resistance (RVR) was calculated from mean arterial pressure (MAP) and renal plasma flow.

Results: Ang II decreased RPF by 34% and GFR by 9% and increased RVR by 94% and MAP by 27% (ANOVA, P < 0.001 vs. baseline, for all parameters). BQ-123 did not alter these renal and systemic haemodynamic responses to a significant degree. In addition, BQ-123 had no significant haemodynamic effect under baseline conditions.

Conclusions: Short-term increase of circulating Ang II levels causes systemic and renal pressor effects, which are not mitigated by endothelin ETA-receptor blockade. This suggests that the pressor response to Ang II cannot be accounted for by the acute release of vasoactive ET-1.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Angiotensin II / pharmacology*
  • Cross-Over Studies
  • Double-Blind Method
  • Endothelin Receptor Antagonists*
  • Endothelin-1 / physiology*
  • Glomerular Filtration Rate / drug effects
  • Hemodynamics / drug effects
  • Humans
  • Inulin
  • Male
  • Peptides, Cyclic / pharmacology
  • Renal Circulation / drug effects
  • Renal Plasma Flow / drug effects
  • Vascular Resistance / drug effects
  • p-Aminohippuric Acid

Substances

  • Endothelin Receptor Antagonists
  • Endothelin-1
  • Peptides, Cyclic
  • Angiotensin II
  • Inulin
  • cyclo(Trp-Asp-Pro-Val-Leu)
  • p-Aminohippuric Acid